Member Info for Laura2022

Rivaldo etc

Good morning , you clearly are excellent at value situations as I have seen your posts elsewhere

Shroders had 13mln left but 10mln+ of that went from 4th Sept to the day of the RNS

As people have suggested, it looks like they are out

Wimbledon

Good morning, it think HE1 and TGP move tosy amd next week

It looks like they will move HE1 50% + as they change tactics on the CLNS

Maybe even look to cancel it ?

Good news ?

Good risk/reward here

Breakout day today ?

Very little stock suggests the last of Shroder is going to a buyer

Therefore ive added another lot

If HE1 finishes flat /blue today it could suggest a several in the huge collapse from 1.2p to 0.3p

JF

Into close they were taking 160,000 well above 5p and was NT to buy many tine s

The first UK Mathematical Biology Conference in Birmingham was a fantastic opportunity to reflect on where the field is heading.

Over two days, we explored how mathematical modelling is being applied in oncology and beyond – from predicting treatment outcomes and enhancing immunotherapies, to new data-driven approaches in bioinformatics and machine learning.

🗨️ A particular highlight was a presentation by Professor Gibin Powathil on hybrid cell-based modelling used to explore treatment effects, such as radiotherapy, chemotherapy and radiation-induced bystander effects on tumour cell growth. Discussions across the two days emphasised that modelling critically offers the ability to explore testable hypotheses in areas where biology remains less well understood.

These themes align closely with our work at Physiomics plc, where we apply modelling to design better studies, reduce uncertainty and help bring promising treatments to patients faster.

We’re looking forward to continuing the conversation at our next events:

📍 ACoP (Annual Conference of the International Society of Pharmacometrics), 18–21 Oct

📍 BIO-Europe, Vienna, 3–5 Nov

If you’re attending, we’d love to connect and discuss how modelling can inform better study design and accelerate development. 🙌

As you saw with other pharmas, they were dormant then sprang to life

Hope youre doing good

Seller nearly done

Looking ahead to the rest of the financial year, the addressable order volume and value across our markets is significant with a visible pipeline of over £400m, of which in excess of £50m of projects are scheduled for award in the second half of this calendar year. We have a number of significant tender opportunities across all revenue lines as well as a material volume of "in and out" work.

Now bidding 4.95p for 150,000

£10mln today

A free hold asset being held for sale at £2.8mln

The current market value looks severely undervalued

"Interim results announced on 26 June 2025, Tekmar highlighted the increasing strength of its visible pipeline, with in excess of £50m of projects scheduled for award in the second half of the calendar year to December 2025".

Bill

£50mln worth of contracts H2

Total pipeline of £400mln going forward

I like look of it based on last results and similar sector to ALRT + A.I

Davey

As you saw on rcfx..I'm happy to be patient:)

Jvip

Morning

Do u think TRAC worth buying.. its A.I security?

Understandable given the rise

Pharmas are catching a light....PYC at £1.3mln so undervalued

Should see past 6p today

Let's see

There should be a switch to the upside you would think after relentless falls from 1.5p

JF

With 8mln volume today and a delayed 200k

Wouldn't imagine it will take long

Under 5.5p to buy won't last long

Looking ahead to the rest of the financial year, the addressable order volume and value across our markets is significant with a visible pipeline of over £400m, of which in excess of £50m of projects are scheduled for award in the second half of this calendar year. We have a number of significant tender opportunities across all revenue lines as well as a material volume of "in and out" work.